MindWalk (NASDAQ:HYFT) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research lowered shares of MindWalk (NASDAQ:HYFT) from a hold rating to a strong sell rating in a research note published on Monday,Zacks.com reports.

MindWalk Trading Down 6.5%

HYFT stock traded down $0.14 during trading on Monday, hitting $2.00. 701,175 shares of the company’s stock traded hands, compared to its average volume of 960,888. MindWalk has a 52 week low of $0.27 and a 52 week high of $3.25.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.